BACKGROUND: Deregulation of c-myc plays a major role in the carcinogenesis of human malignancies. We investigated the amplification of the c-myc gene in a surgical series of Barrett cancers. METHODS: Primary resected esophageal (Barrett) adenocarcinomas (n = 84) were investigated for c-myc amplification using chromogene in situ hybridization. Tumor samples were assembled in a tissue microarray. c-myc gene dosage was correlated with clinicopathologic parameters, including the survival and gene expression of cyclooxygenases (COX-1 and COX-2) and proangiogenic growth factors (VEGF-A and VEGF-C). RESULTS: The majority (70 of 84; 83.3%) exhibited amplification of the c-myc gene. There were low-level amplifications in 63 (75.0%) cases and high-level amplifications in 7 (8.3%) cases. No amplification was found in 14 (16.7%) cases. Tumors without c-myc amplification had lower VEGF-A, VEGF-C, and COX-2 expression levels than tumors with low-level and high-level c-myc amplification (statistically significant for VEGF-A; P = .0348). c-myc amplification was not correlated with clinicopathological parameters or survival. Only diffuse and mixed-type tumors, according to Lauren classification, exhibited c-myc amplifications more frequently (P = .0466). CONCLUSIONS: Amplifications of the c-myc gene are frequent in Barrett cancer. c-myc may be involved in the regulation of angiogenesis.
BACKGROUND: Deregulation of c-myc plays a major role in the carcinogenesis of humanmalignancies. We investigated the amplification of the c-myc gene in a surgical series of Barrett cancers. METHODS: Primary resected esophageal (Barrett) adenocarcinomas (n = 84) were investigated for c-myc amplification using chromogene in situ hybridization. Tumor samples were assembled in a tissue microarray. c-myc gene dosage was correlated with clinicopathologic parameters, including the survival and gene expression of cyclooxygenases (COX-1 and COX-2) and proangiogenic growth factors (VEGF-A and VEGF-C). RESULTS: The majority (70 of 84; 83.3%) exhibited amplification of the c-myc gene. There were low-level amplifications in 63 (75.0%) cases and high-level amplifications in 7 (8.3%) cases. No amplification was found in 14 (16.7%) cases. Tumors without c-myc amplification had lower VEGF-A, VEGF-C, and COX-2 expression levels than tumors with low-level and high-level c-myc amplification (statistically significant for VEGF-A; P = .0348). c-myc amplification was not correlated with clinicopathological parameters or survival. Only diffuse and mixed-type tumors, according to Lauren classification, exhibited c-myc amplifications more frequently (P = .0466). CONCLUSIONS: Amplifications of the c-myc gene are frequent in Barrett cancer. c-myc may be involved in the regulation of angiogenesis.
Authors: Burkhard H A von Rahden; Hubert J Stein; Franziska Pühringer; Ina Koch; Rupert Langer; Guido Piontek; J Rüdiger Siewert; Heinz Höfler; Mario Sarbia Journal: Cancer Res Date: 2005-06-15 Impact factor: 12.701
Authors: A K Walch; H F Zitzelsberger; J Bruch; G Keller; D Angermeier; M M Aubele; J Mueller; H Stein; H Braselmann; J R Siewert; H Höfler; M Werner Journal: Am J Pathol Date: 2000-02 Impact factor: 4.307
Authors: Maria E Vega; Véronique Giroux; Mitsuteru Natsuizaka; Mingen Liu; Andres J Klein-Szanto; Douglas B Stairs; Hiroshi Nakagawa; Kenneth K Wang; Timothy C Wang; John P Lynch; Anil K Rustgi Journal: Cell Cycle Date: 2014 Impact factor: 4.534
Authors: Nicole E Hurley; Lisa A Schildmeyer; Kami A Bosworth; Yumiko Sakurai; Suzanne G Eskin; Laurence H Hurley; Larry V McIntire Journal: J Vasc Res Date: 2009-09-03 Impact factor: 1.934
Authors: Eric M Thompson; Stephen T Keir; Talaignair Venkatraman; Christopher Lascola; Kristen W Yeom; Andrew B Nixon; Yingmiao Liu; Daniel Picard; Marc Remke; Darell D Bigner; Vijay Ramaswamy; Michael D Taylor Journal: Neuro Oncol Date: 2017-09-01 Impact factor: 12.300